Pressure BioSciences, Inc. (PBIO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pressure BioSciences, Inc. (PBIO) trades at $0.0004 with AI Score 50/100 (Grade B). Pressure BioSciences, Inc. develops and sells pressure-based platform solutions, primarily its pressure cycling technology (PCT), to researchers in North America, Europe, and Asia. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for PBIO: PBIO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PBIO against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
PBIO: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Pressure BioSciences, Inc. (PBIO) Healthcare & Pipeline Overview
Pressure BioSciences, Inc. (PBIO) offers pressure-based platform solutions using its pressure cycling technology (PCT) for biological sample processing, targeting academic, government, and pharmaceutical research sectors across North America, Europe, and Asia, while operating as a subsidiary of Emergent Health Corp.
What Is the Investment Thesis for PBIO?
Pressure BioSciences, Inc. presents a focused investment opportunity within the life sciences research tools market. The company's pressure cycling technology (PCT) offers a unique approach to sample preparation, potentially driving adoption in research labs. Key value drivers include expanding the installed base of Barocycler instruments and increasing sales of associated consumables. Growth catalysts include ongoing collaborations with research institutions and potential expansion into new applications. However, investors may want to evaluate the company's negative profit margin of -1482.2% and its position as an OTC-traded stock, which entails higher risks. The company's small market capitalization and limited number of employees (15) also present challenges.
Based on FMP financials and quantitative analysis
PBIO Key Highlights
Gross Margin of 40.4% indicates a solid pricing strategy and cost control in the production of its pressure-based platform solutions.
- Operates as a subsidiary of Emergent Health Corp. since August 2, 2022, potentially providing access to additional resources and strategic guidance.
- Beta of -0.10 suggests the stock price is less volatile than the market, which may appeal to risk-averse investors.
- Serves diverse customer base including academic labs, government agencies, biotech firms, and pharmaceutical companies, reducing reliance on a single customer segment.
- Collaborations with RedShiftBio Inc., Inova Schar Cancer Center, NYU, and other institutions validate the technology and expand market reach.
Who Are PBIO's Competitors?
PBIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MDGEF Medigene AG | $2.59 | +0.00% | $38.2M | 48 |
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PBIO's Key Strengths?
Proprietary pressure cycling technology (PCT).
- Established relationships with research institutions.
- Recurring revenue from consumables.
- Specialized expertise in pressure-based sample processing.
What Are PBIO's Weaknesses?
Negative profit margin.
- Small market capitalization.
- Limited number of employees.
- OTC-traded stock with associated risks.
What Could Drive PBIO Stock Higher?
Expansion of Barocycler instrument sales to academic and pharmaceutical labs.
- Increased sales of Barocycler consumables, driving recurring revenue.
- Strategic collaborations with research institutions and biotechnology companies.
- Development of new applications for PCT technology in diagnostics and bioprocessing.
What Are the Key Risks for PBIO?
Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from alternative sample preparation methods.
- Technological obsolescence of PCT technology.
- Regulatory changes affecting the medical device industry.
- Economic downturn affecting research funding.
- Negative profit margin and limited financial resources.
What Are the Growth Opportunities for PBIO?
- Expansion of Barocycler Instrument Sales: Pressure BioSciences can grow by increasing the installed base of its Barocycler instruments. The market for advanced sample preparation tools is expanding, driven by the increasing complexity of biological research. By targeting academic and pharmaceutical labs, PBIO can increase its instrument sales. This growth opportunity is ongoing and directly related to the company's core product offering.
- Increased Consumables Revenue: A significant growth opportunity lies in increasing the sales of Barocycler consumables, such as PCT MicroTubes and MicroCaps. As the installed base of Barocycler instruments grows, the demand for these consumables will also increase. This recurring revenue stream can provide a stable source of income for the company. This is an ongoing opportunity with a direct link to instrument sales.
- Strategic Collaborations and Partnerships: Forming strategic collaborations with research institutions and biotechnology companies can drive growth. These partnerships can validate the company's technology, expand its market reach, and lead to new applications for its PCT platform. The company's existing collaborations with RedShiftBio Inc. and NYU demonstrate the potential of this strategy. This is an ongoing opportunity.
- Expansion into New Applications: Pressure BioSciences can expand its market by developing new applications for its PCT technology. This could include applications in areas such as diagnostics, forensics, and bioprocessing. By diversifying its application portfolio, the company can reduce its reliance on specific research areas. This is an ongoing opportunity that requires further research and development.
- Geographic Expansion: Pressure BioSciences already has a presence in North America, Europe, and Asia. However, there is potential to further expand its geographic reach, particularly in emerging markets. By targeting research institutions and biotechnology companies in these regions, the company can tap into new sources of revenue. This is an ongoing opportunity that requires careful market analysis and strategic partnerships.
What Are PBIO's Competitive Advantages?
- Proprietary pressure cycling technology (PCT) offers a unique approach to sample preparation.
- Established relationships with research institutions and biotechnology companies.
- Recurring revenue stream from Barocycler consumables.
- Specialized expertise in pressure-based biological sample processing.
What Does PBIO Do?
Pressure BioSciences, Inc., incorporated in 1978 and based in South Easton, Massachusetts, develops and sells pressure-based platform solutions. The company's core technology, pressure cycling technology (PCT), utilizes alternating cycles of hydrostatic pressure to control molecular actions within biological samples. These samples include cells and tissues from human, animal, plant, and microbial sources. PBIO offers a range of Barocycler instrumentations, including the Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. In addition to instrumentation, the company distributes cell disruption equipment, parts, and consumables, along with Barocycler consumable products like PCT MicroTubes, PCT MicroCaps, and PCT-Micro Pestle. These products are designed to lyse samples for extraction. PBIO also provides application-specific kits that include consumable products and reagents. The company serves researchers in academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. Pressure BioSciences collaborates with various organizations, including RedShiftBio Inc., Inova Schar Cancer Center, NYU, Leica Microsystems, GmbH, Steinbeis Centre for biopolymer analysis and biological mass spectrometry, The Ohio State University, University of Delaware, and Cedars Sinai Medical Center. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.
What Products and Services Does PBIO Offer?
- Develops pressure-based platform solutions for biological sample preparation.
- Offers pressure cycling technology (PCT) using alternating cycles of hydrostatic pressure.
- Provides Barocycler instrumentations like Barocycler 2320EXT and HUB880.
- Distributes cell disruption equipment, parts, and consumables.
- Offers Barocycler consumable products such as PCT MicroTubes and MicroCaps.
- Serves researchers in academic laboratories, government agencies, and pharmaceutical firms.
- Collaborates with research institutions and biotechnology companies.
How Does PBIO Make Money?
- Sells Barocycler instruments to research institutions and biotechnology companies.
- Generates recurring revenue through the sale of Barocycler consumables.
- Forms strategic collaborations to expand market reach and develop new applications.
- Provides application-specific kits that include consumable products and reagents.
What Industry Does PBIO Operate In?
Pressure BioSciences operates within the medical devices industry, specifically focusing on tools and technologies for biological sample preparation. The market for sample preparation is driven by increasing research activity in genomics, proteomics, and drug discovery. Competition includes companies offering alternative methods for cell lysis and protein extraction. Pressure BioSciences differentiates itself with its pressure cycling technology (PCT), which offers advantages in terms of efficiency and reproducibility. The industry is characterized by continuous innovation and the need for technologies that can handle increasingly complex biological samples.
Who Are PBIO's Key Customers?
- Academic laboratories
- Government agencies
- Biotechnology companies
- Pharmaceutical firms
- Life science institutions
Forward Outlook
Wall Street analysts project Pressure BioSciences, Inc. revenue of about $2.7M for fiscal 2026, with EPS near $-4.20.
Earnings Track Record
Pressure BioSciences, Inc. has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 97.9% below estimates on average.
Financial Health
Pressure BioSciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Pressure BioSciences, Inc. stands at 89.6%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching.
Pressure BioSciences, Inc. (PBIO) Valuation Context
Relative to its peer group, PBIO's quantitative score of 50/100 is roughly in line with the peer average of 60/100.
PBIO Revenue & Earnings Trend
In Q2 2024, PBIO generated $422K in top-line revenue, marking a sequential increase of 20.8%. The company recorded a net loss of $7.1M, with diluted EPS of $-0.15.
Company Profile
Pressure BioSciences, Inc. operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Canton, US. The company is led by CEO Richard T. Schumacher. PBIO has traded publicly since 1996.
PBIO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's growth potential, indicating that management believes in its future prospects.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments that could enhance market position.
- The company has recently secured partnerships that could expand its reach and improve revenue streams, fostering optimism among investors.
- Increased media coverage has spotlighted Pressure BioSciences' technology, generating heightened interest and enthusiasm within the trading community.
Bear Case
- Concerns about the company's ability to scale operations effectively have surfaced, leading some investors to question long-term viability.
- Recent earnings reports have not met market expectations, causing disappointment and skepticism among traders regarding future performance.
- Social sentiment has shown signs of volatility, with bearish opinions emerging around the sustainability of recent partnerships and their impact.
- The competitive landscape in the biotech sector remains fierce, raising concerns about Pressure BioSciences' ability to differentiate itself and capture market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | $421,792 | -$7M | -$0.15 |
| Q1 2024 | $349,257 | -$8M | -$0.22 |
Based on FMP financials and quantitative analysis
PBIO Latest News
No recent news available for PBIO.
PBIO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PBIO.
Price Targets
Wall Street price target analysis for PBIO.
PBIO MoonshotScore
What does this score mean?
The MoonshotScore rates PBIO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Richard T. Schumacher
Unknown
Information about Richard T. Schumacher's background is not available in the provided data. Therefore, a detailed biography cannot be constructed. His career history, education, previous roles, and credentials are unknown based on the provided source material.
Track Record: Information about Richard T. Schumacher's track record is not available in the provided data. Key achievements, strategic decisions, and company milestones under his leadership cannot be assessed based on the provided source material.
PBIO OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Pressure BioSciences may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the potential for fraud, lack of liquidity, and limited information.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in PBIO.
- Low trading volume can lead to price volatility and difficulty in executing trades.
- Potential for fraud or manipulation is higher in the OTC market.
- PBIO may not meet the listing requirements of major exchanges, indicating potential financial or operational challenges.
- The OTC Other tier has less regulatory oversight compared to listed exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's liquidity and trading volume.
- Review any legal or regulatory actions involving the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- The company has been in operation since 1978.
- PBIO has established collaborations with reputable research institutions.
- The company's pressure cycling technology (PCT) is used in various research applications.
- PBIO operates as a subsidiary of Emergent Health Corp.
PBIO Healthcare Stock FAQ
What does the AI Score mean for PBIO?
PBIO holds an AI Score of 50/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Pressure BioSciences, Inc. develops and sells pressure-based platform solutions, primarily its pressure cycling technology (PCT), to researchers in North America, Europe, and Asia. The company's …
What does Pressure BioSciences, Inc. do?
Pressure BioSciences, Inc. (PBIO) develops, manufactures, and sells pressure-based platform solutions for biological sample preparation. Its core technology, pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure to control molecular actions in biological samples. The company offers Barocycler instruments, consumables, and application-specific kits to researchers in academic laboratories, government agencies, biotechnology companies, and pharmaceutical firms.
What are the main risks for PBIO?
The main risks for Pressure BioSciences, Inc. include its negative profit margin, small market capitalization, and limited number of employees. As an OTC-traded stock, PBIO faces higher risks related to liquidity, price volatility, and regulatory oversight. Competition from alternative sample preparation methods and the potential for technological obsolescence also pose challenges.
What are the key factors to evaluate for PBIO?
Pressure BioSciences, Inc. (PBIO) holds an AI score of 50/100 (moderate). presents a focused investment opportunity within the life sciences research tools market. Not financial advice.
How frequently does PBIO data refresh on this page?
PBIO's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PBIO's recent stock price performance?
Pressure BioSciences, Inc. (PBIO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary pressure cycling technology (PCT). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PBIO overvalued or undervalued right now?
Pressure BioSciences, Inc. (PBIO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PBIO before investing?
Before investing in Pressure BioSciences, Inc. (PBIO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding PBIO to a portfolio?
Key strength of Pressure BioSciences, Inc. (PBIO): Proprietary pressure cycling technology (PCT). Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be up-to-date.
- OTC market investments carry significant risks.